Novan Inc: Up on positive data from COVID-19 treatment study in hamsters

NVN Liquidation

10/06/2021 14:43

** Biotech co's  NOVN.O  shares rise 5.06% to $9.31
    ** Co reports positive preclinical results with intranasal
treatment berdazimer sodium in golden Syrian hamsters with
SARS-CoV-2  urn:newsml:reuters.com:*:nGNX8thZh3
    ** NOVN evaluated potential of its NITRICIL platform
technology to administer berdazimer sodium intranasally 
    ** Says data shows berdazimer sodium prevents progression of
SARS-CoV-2 infection and there was a statistically significant
reduction in the amount of virus in the lung with low doses 
    ** Following results, co says exploring opportunities to
develop anti-viral therapy against COVID-19, both internally and
potentially through strategic partnerships 
    ** NOVN stock up about 9% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))